(SPRY) ARS Pharmaceuticals - Ratings and Ratios
Cancer Antibody,Immune Activator,Clinical Trials
Description: SPRY ARS Pharmaceuticals August 13, 2025
Silverback Therapeutics Inc (NASDAQ:SPRY) is a biotechnology company listed on the NASDAQ stock exchange. The companys stock performance is characterized by significant volatility, as reflected in its average true range (ATR) of 3.91%. This volatility is a key consideration for investors, as it impacts the stocks risk profile.
The biotechnology industry is known for its high-risk, high-reward nature, driven by factors such as the success of clinical trials, regulatory approvals, and market demand for innovative treatments. Key economic drivers for Silverback Therapeutics include the development and commercialization of its product pipeline, partnerships with other industry players, and the overall landscape of the biotechnology sector.
To evaluate the companys financial health, investors should focus on key performance indicators (KPIs) such as revenue growth, research and development (R&D) expenses, and cash burn rate. The companys return on equity (RoE) of -6.94% indicates that it is currently operating at a loss, which is not uncommon for biotechnology companies in the development stage.
From a valuation perspective, the companys price-to-earnings (P/E) ratio is not meaningful due to its negative earnings. Investors should consider alternative metrics, such as the enterprise value-to-R&D expenses ratio, to assess the companys valuation relative to its investment in product development.
The companys market capitalization of $1.73 billion suggests a significant level of investor interest and confidence in its prospects. However, investors should carefully consider the risks and uncertainties associated with investing in a biotechnology company, including the potential for clinical trial failures, regulatory setbacks, and market competition.
SPRY Stock Overview
| Market Cap in USD | 1,144m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-12-04 |
SPRY Stock Ratings
| Growth Rating | 10.2% |
| Fundamental | 29.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -50.0% |
| Analyst Rating | 4.83 of 5 |
SPRY Dividends
Currently no dividends paidSPRY Growth Ratios
| Growth Correlation 3m | -78.6% |
| Growth Correlation 12m | -10.1% |
| Growth Correlation 5y | 3% |
| CAGR 5y | 14.20% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.21 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.64 |
| Sharpe Ratio 12m | -0.07 |
| Alpha | -61.14 |
| Beta | 0.841 |
| Volatility | 63.37% |
| Current Volume | 1924k |
| Average Volume 20d | 2191.2k |
| Stop Loss | 8.5 (-6.7%) |
| Signal | -0.98 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-48.0m TTM) > 0 and > 6% of Revenue (6% = 6.74m TTM) |
| FCFTA -0.17 (>2.0%) and ΔFCFTA 2.90pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 209.9% (prev 45.5k%; Δ -45.3kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.17 (>3.0%) and CFO -52.8m <= Net Income -48.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.17 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (98.4m) change vs 12m ago 1.58% (target <= -2.0% for YES) |
| Gross Margin 93.72% (prev 86.81%; Δ 6.91pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 41.96% (prev 0.21%; Δ 41.75pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -6.38 (EBITDA TTM -54.7m / Interest Expense TTM -8.87m) >= 6 (WARN >= 3) |
Altman Z'' -0.34
| (A) 0.75 = (Total Current Assets 281.4m - Total Current Liabilities 45.6m) / Total Assets 313.5m |
| (B) -0.64 = Retained Earnings (Balance) -202.1m / Total Assets 313.5m |
| (C) -0.21 = EBIT TTM -56.6m / Avg Total Assets 267.7m |
| (D) -1.67 = Book Value of Equity -202.2m / Total Liabilities 121.2m |
| Total Rating: -0.34 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 29.73
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -5.89% = -2.95 |
| 3. FCF Margin -47.52% = -7.50 |
| 4. Debt/Equity 0.01 = 2.50 |
| 5. Debt/Ebitda 0.91 = 1.88 |
| 6. ROIC - WACC (= -33.96)% = -12.50 |
| 7. RoE -21.85% = -2.50 |
| 8. Rev. Trend 79.40% = 5.96 |
| 9. EPS Trend -33.33% = -1.67 |
What is the price of SPRY shares?
Over the past week, the price has changed by -9.35%, over one month by -5.40%, over three months by -49.16% and over the past year by -40.84%.
Is ARS Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SPRY is around 8.09 USD . This means that SPRY is currently overvalued and has a potential downside of -11.2%.
Is SPRY a buy, sell or hold?
- Strong Buy: 5
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the SPRY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 31.3 | 243.9% |
| Analysts Target Price | 31.3 | 243.9% |
| ValueRay Target Price | 9.1 | -0.4% |
SPRY Fundamental Data Overview October 11, 2025
P/S = 10.1871
P/B = 5.2825
Beta = 0.841
Revenue TTM = 112.3m USD
EBIT TTM = -56.6m USD
EBITDA TTM = -54.7m USD
Long Term Debt = 1.66m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 589.0k USD (from shortTermDebt, last quarter)
Debt = 1.66m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -49.9m USD (from netDebt column, last quarter)
Enterprise Value = 905.9m USD (1.14b + Debt 1.66m - CCE 240.1m)
Interest Coverage Ratio = -6.38 (Ebit TTM -56.6m / Interest Expense TTM -8.87m)
FCF Yield = -5.89% (FCF TTM -53.4m / Enterprise Value 905.9m)
FCF Margin = -47.52% (FCF TTM -53.4m / Revenue TTM 112.3m)
Net Margin = -42.74% (Net Income TTM -48.0m / Revenue TTM 112.3m)
Gross Margin = 93.72% ((Revenue TTM 112.3m - Cost of Revenue TTM 7.05m) / Revenue TTM)
Gross Margin QoQ = 68.29% (prev 86.28%)
Tobins Q-Ratio = 2.89 (Enterprise Value 905.9m / Total Assets 313.5m)
Interest Expense / Debt = 225.9% (Interest Expense 3.75m / Debt 1.66m)
Taxrate = 3.48% (288.0k / 8.29m)
NOPAT = -54.6m (EBIT -56.6m * (1 - 3.48%)) [loss with tax shield]
Current Ratio = 6.17 (Total Current Assets 281.4m / Total Current Liabilities 45.6m)
Debt / Equity = 0.01 (Debt 1.66m / totalStockholderEquity, last quarter 192.3m)
Debt / EBITDA = 0.91 (negative EBITDA) (Net Debt -49.9m / EBITDA -54.7m)
Debt / FCF = 0.93 (negative FCF - burning cash) (Net Debt -49.9m / FCF TTM -53.4m)
Total Stockholder Equity = 219.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -15.32% (Net Income -48.0m / Total Assets 313.5m)
RoE = -21.85% (Net Income TTM -48.0m / Total Stockholder Equity 219.8m)
RoCE = -25.56% (EBIT -56.6m / Capital Employed (Equity 219.8m + L.T.Debt 1.66m))
RoIC = -24.86% (negative operating profit) (NOPAT -54.6m / Invested Capital 219.8m)
WACC = 9.10% (E(1.14b)/V(1.15b) * Re(9.11%) + (debt cost/tax rate unavailable))
Discount Rate = 9.11% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.15%
Fair Price DCF = unknown (Cash Flow -53.4m)
EPS Correlation: -33.33 | EPS CAGR: -29.49% | SUE: 1.83 | # QB: 1
Revenue Correlation: 79.40 | Revenue CAGR: 399.1% | SUE: 0.08 | # QB: 0
Additional Sources for SPRY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle